Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugs

Journal of the Royal Society Interface

Volumn 13, Issue 119, 2016, Pages

  Tekin, Elif ^a   Beppler, Casey ^b   White, Cynthia ^b   Mao, Zhiyuan ^b   Savage, Van M ^a,b,c   Yeh, Pamela J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SANTA FE INSTITUTE   (United States)

Author keywords

Antibiotics; Drug resistance; Higher order interactions

Indexed keywords

ANTIBIOTICS; BIOASSAY; DRUG THERAPY;

BACTERIAL GROWTH; CONCEPTUAL FRAMEWORKS; DRUG COMBINATIONS; DRUG RESISTANCE; EMERGENT INTERACTIONS; HIGHER-ORDER; PAIRWISE INTERACTION; RESCALING METHOD;

DRUG INTERACTIONS;

AMPICILLIN; ANTIBIOTIC AGENT; CEFOXITIN; CHLORAMPHENICOL HEMISUCCINATE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE HYCLATE; ERYTHROMYCIN; FUSIDATE SODIUM; GENTAMICIN; NITROFURANTOIN; STREPTOMYCIN SULFATE; TOBRAMYCIN SULFATE; TRIMETHOPRIM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL GROWTH; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; ESCHERICHIA COLI; GROWTH RATE; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; NONHUMAN; GROWTH, DEVELOPMENT AND AGING; PRECLINICAL STUDY;

ANTI-BACTERIAL AGENTS; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ESCHERICHIA COLI;

EID: 84983087709     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2016.0332     Document Type: Article

References (50)

1. Hammer SM et al. 1997 A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337, 725-733. (doi:10.1056/NEJM199709113371101)
2. Diacon AH et al. 2012 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380, 986-993. (doi:10.1016/S0140-6736(12)61080-0)
3. Hamoud R, Zimmermann S, Reichling J, Wink M. 2014 Synergistic interactions in two-drug and three-drug combinations (thymol, EDTA and vancomycin) against multi drug resistant bacteria including E. coli. Phytomedicine 21, 443-447. (doi:10.1016/j.phymed.2013.10.016)
4. Cohen CJ, Bruckner HW, Deppe G, Blessing JA, Homesley H, Lee JH, Watring W. 1984 Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Obstet. Gynecol. 63, 719-726.
5. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. 2006 Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466. (doi:10.1038/nchembio817)
6. Bliss CI. 1939 The toxicity of poisons applied jointly. Ann. Appl.Biol. 2, 585-615.
7. Kalan L, Wright G. 2011 Antibiotic adjuvants: multicomponent anti-infective strategies. Expert Rev. Mol. Med. 13, e5. (doi:10.1017/S1462399410001766)
8. Yeh P, Tschumi A, Kishony R. 2006 Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 38, 489-494. (doi:10.1038/ng1755)
9. Walsh C. 2000 Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775-781. (doi:10.1038/35021219)
10. Nathan C. 2004 Antibiotics at the crossroads. Nature 431, 899-902. (doi:10.1038/431899a)
11. Keith CT, Borisy AA, Stockwell BR. 2005 Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discovery 4,71-78. (doi:10.1038/nrd1609)
12. Loewe S. 1953 The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3, 285-290.
13. Greco WR, Bravo G, Parsons JC. 1995 The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385.
14. Beppler C et al. Submitted. Uncovering emergent interactions in three-way combinations of stressors: a shift to greater antagonism.
15. Bollenbach T, Quan S, Chait R, Kishony R. 2009 Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. Cell 139, 707-718. (doi:10.1016/j.cell.2009.10.025)
16. Fraser TR. 1872 Lecture on the antagonism between the actions of active substances. Br. Med. J. 2, 485-487. (doi:10.1136/bmj.2.618.485)
17. Yeh P, Hegreness M, Aiden A, Kishony R. 2009 Drug interactions and the evolution of antibiotic resistance. Nat. Rev. Microbiol. 7, 460-466. (doi:10.1038/nrmicro2133)
18. Segre D, DeLuna A, Church G, Kishony R. 2005 Modular epistasis in yeast metabolism. Nat. Genet. 37, 77-83. (doi:10.1038/ng1489)
19. Tyler AL, Asselbergs FW, Williams SM, Moore JH. 2009 Shadows of complexity: what biological networks reveal about epistasis and pleiotropy. Bioessays 31, 220-227. (doi:10.1002/bies.200800022)
20. He X, Qian W, Wang Z, Li Y, Zhang J. 2010 Prevalent positive epistasis in Escherichia coli and Saccharomyces cerevisiae metabolic networks. Nat. Genet. 42, 272-276. (doi:10.1038/ng.524)
21. Sanjuán R, Elena SF. 2006 Epistasis correlates to genomic complexity. Proc. Natl Acad. Sci. USA 103, 14 402-14 405. (doi:10.1073/pnas.0604543103)
22. Podgornaia AI, Laub MT. 2015 Pervasive degeneracy and epistasis in a protein-protein interface. Science 347, 673-677. (doi:10.1126/science.1257360)
23. Sih A, Englund G, Wooster D. 1998 Emergent impacts of multiple predators on prey. Trends Ecol. Evol. 13, 350-355. (doi:10.1016/S0169-5347(98)01437-2)
24. Sokol-Hessner L, Schmitz OJ. 2002 Aggregate effects of multiple predator species on a shared prey. Ecology 83, 2367-2372. (doi:10.1890/0012-9658(2002)083[2367:AEOMPS]2.0.CO;2)
25. Son TC, Thiel M. 2006 Multiple predator effects in an intertidal food web. J. Anim. Ecol. 75, 25-32. (doi:10.1111/j.1365-2656.2005.01019.x)
26. Gunzburger M, Travis J. 2005 Effects of multiple predator species on green treefrog (Hyla cinerea) tadpoles. Can. J. Zool. 83, 996-1002. (doi:10.1139/z05-093)
27. Soluk DA. 1993 Multiple predator effects: predicting combined functional response of stream fish and invertebrate predators. Ecology 74, 219-225. (doi:10.2307/1939516)
28. Wood K, Nishida S, Sontag ED, Cluzel P. 2012 Mechanism-independent method for predicting response to multidrug combinations in bacteria. Proc. Natl Acad. Sci. USA 109, 12 254-12 259. (doi:10.1073/pnas.1201281109)
29. Sanjuán R, Nebot MR. 2008 A network model for the correlation between epistasis and genomic complexity. PLoS ONE 3, e2663. (doi:10.1371/journal.pone.0002663)
30. Datsenko KA, Wanner BL. 2000 One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl Acad. Sci. USA 97, 6640-6645. (doi:10.1073/pnas.120163297)
31. Baba T et al. 2006 Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006.0008. (doi:10.1038/msb4100050)
32. Zhou A, Kang TM, Yuan J, Beppler C, Nguyen C, Mao Z, Nguyen MQ, Yeh P, Miller JH. 2015 Synergistic interactions of vancomycin with different antibiotics against Escherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli. Antimicrob. Agents Chemother. 59, 276-281. (doi:10.1128/AAC.03502-14)
33. Lázár V et al. 2013 Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol. 9, 700. (doi:10.1038/msb.2013.57)
34. Ocampo PS et al. 2014 Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. Antimicrob. Agents Chemother. 58, 4573-4582. (doi:10.1128/AAC.02463-14)
35. Joshi CJ, Prasad A. 2014 Epistatic interactions among metabolic genes depend upon environmental conditions. Mol. Biosyst. 10, 2578-2589. (doi:10.1039/C4MB00181H)
36. Hammer SM et al. 1996 A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N. Engl. J. Med. 335, 1081-1090. (doi:10.1056/NEJM199610103351501)
37. Klein F et al. 2012 HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118-122. (doi:10.1038/nature11604)
38. Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, Rousseau F. 2006 An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. Aids 20, 2051-2064. (doi:10.1097/01.aids.0000247578.08449.ff)
39. Gulick RM et al. 2004 Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350, 1850-1861. (doi:10.1056/NEJMoa031772)
40. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, González-Lahoz J. 2000 Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. Aids 14, 807-812. (doi:10.1097/00002030-200005050-00006)
41. Chait R, Craney A, Kishony R. 2007 Antibiotic interactions that select against resistance. Nature 446, 668-671. (doi:10.1038/nature05685)
42. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R. 2008 Accelerated evolution of resistance in multidrug environments. Proc. Natl Acad. Sci. USA 105, 13 977-13 981. (doi:10.1073/pnas.0805965105)
43. Michel J-B, Yeh PJ, Chait R, Moellering RC, Kishony R. 2008 Drug interactions modulate the potential for evolution of resistance. Proc. Natl Acad. Sci. USA 105, 14 918-14 923. (doi:10.1073/pnas.0800944105)
44. Torella JP, Chait R, Kishony R. 2010 Optimal drug synergy in antimicrobial treatments. PLoS Comput. Biol. 6, e1000796. (doi:10.1371/journal.pcbi.1000796)
45. Brynildsen MP, Winkler JA, Spina CS, MacDonald IC, Collins JJ. 2013 Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production. Nat. Biotechnol. 31, 160-165. (doi:10.1038/nbt.2458)
46. Thangamani S, Younis W, Seleem MN. 2015 Repurposing clinical molecule ebselen to combat drug resistant pathogens. PLoS ONE 10, e0133877. (doi:10.1371/journal.pone.0133877)
47. Bradley WD et al. 2014 EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chem. Biol. 21, 1463-1475. (doi:10.1016/j.chembiol.2014.09.017)
48. Hiss DC, Gabriels GA, Folb PI. 2007 Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. Cancer Cell Int. 7, 1. (doi:10.1186/1475-2867-7-1)
49. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, Shen L, Siliciano RF. 2012 A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat. Med. 18, 446-451. (doi:10.1038/nm.2649)
50. Youn H, Gastner MT, Jeong H. 2008 Price of anarchy in transportation networks: efficiency and optimality control. Phys. Rev. Lett. 101, 128701. (doi:10.1103/PhysRevLett.101.128701)